DCTH Delcath Systems, Inc.

15.38USD-0.19%Mkt Cap: 533.67M $P/E: —

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphala…

Key Statistics

Company
Market Cap533.67M USD
Enterprise Value441.27M USD
Revenue (TTM)95.42M USD
Gross Profit73.43M USD
Net Income (TTM)2.70M USD
Revenue/Share2.64 USD
Last Price15.38 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees156
CountryUS
SectorHealthcare
IndustryMedical Devices
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)342.44
PEG1.60
EV/EBITDA-303.28
EV/Revenue4.62
P/S5.60
P/B4.41
EPS (TTM)0.01
EPS (Forward)0.04
52W Range
8.12078% of range17.42
52W High17.42 USD
52W Low8.120 USD
Profitability
Gross Margin86.16%
Oper. Margin8.22%
EBITDA Margin-1.52%
Profit Margin3.17%
ROE2.43%
ROA2.18%
Growth
Revenue Growth20.60%
Earnings Growth0.00%
Cash Flow & Leverage
Operating CF22.52M USD
CapEx (TTM)1.55M USD
FCF Margin18.99%
FCF Yield3.39%
Net Debt-93.44M USD
Net Debt/EBITDA64.22
Balance Sheet
Debt/Equity0.01
Current Ratio9.83
Quick Ratio8.45
Book Value/Sh3.50 USD
Cash/Share2.76 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateDec 24, 2019
Splits
Last Split1:700
Split DateDec 24, 2019
Analyst Consensus
Rating—
Target (Mean)24.00 USD
Upside (mean)+56.0%
Target Range21.00 USD – 32.00 USD
21.00+56.0% to mean32.00
# Analysts5
Ownership
Shares Out.34.70M
Float28.78M
Insiders8.09%
Institutions51.82%
Short Interest
Short Ratio5.8d
Short % Float7.25%
Short % Out.6.66%
Shares Short2.31M
Short (prev mo.)2.36M
Technical
SMA 5015.66 (-1.8%)
SMA 20011.90 (+29.2%)
Beta0.60
S&P 52W Chg16.45%
Avg Vol (30d)368.54K
Avg Vol (10d)338.82K
Technical Indicators
RSI (14)45.9
MACD-0.0265
MACD Signal0.1103
MACD Hist.-0.1368
BB Upper16.56 USD
BB Middle15.87 USD
BB Lower15.19 USD
BB Width8.62%
ATR (14)0.5376 USD
Vol Ratio (20d)0.76x